Plain-English translation of NCT06107673 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Breast Cancer research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing whether , a new medication that blocks certain cancer-promoting proteins, combined with an (a hormone therapy) works as well as chemotherapy for early breast cancer in postmenopausal women. Half of the participants will receive the new medication approach, and half will receive standard chemotherapy. The goal is to see if this new treatment option is just as effective but potentially easier to tolerate.
Chemotherapy can be very hard on the body, causing serious side effects. Researchers want to know whether this medication, which takes a different approach by blocking hormone signals and specific cancer proteins, might work just as well while being gentler on patients.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will be randomly assigned to receive either the new medication approach or standard chemotherapy. The treatment lasts 24 weeks. If you receive the new medication, you'll take a daily pill for 3 weeks, then have 1 week off, repeating this cycle. If you receive chemotherapy, you'll have intravenous infusions of three cancer drugs on a set schedule. You'll have regular clinic visits to check your health and monitor how well the treatment is working.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
China